^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DO-2
i
Other names: DO-2, deuterated OMO-2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
DeuterOncology, J&J, Octimet
Drug class:
c-MET inhibitor, RAS inhibitor
Related drugs:
2ms
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours (clinicaltrials.gov)
P1, N=25, Recruiting, DeuterOncology | N=15 --> 25 | Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Oct 2024
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
MET mutation
|
DO-2
12ms
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours (clinicaltrials.gov)
P1, N=15, Recruiting, DeuterOncology | Active, not recruiting --> Recruiting | Trial completion date: Jun 2024 --> Nov 2024
Enrollment open • Trial completion date • Metastases
|
MET mutation
|
DO-2
Share via
